NYSE : BDX

Becton, Dickinson and Company

$156.36 USD

$3.39 (2.22%)

Volume
1.11M
Average Volume
2.76M
Market Capitalization
$56.65B
P/E Ratio
39.58
Dividend Yield
2.39%
Price Target
$175.00
Year High
$187.35
Year Low
$127.59
Day High
—
Day Low
—
Payout Ratio
$1.04
Current Ratio
$0.94
Company Overview

NYSE

Thomas E. Polen Jr.

Medical - Instruments & Supplies

Healthcare

BDX

72000

US

USD

https://www.bd.com

201 847 6800

075887109

0000010795

Liquidity Metrics

0.72

0.94

0.55

0.10

1.04

Sales & Valuation

$21.84B

2.65

1.82

18.03

11.20

Profitability

$5.83

$1.68B

5.33%

8.14%

4.54%

2.24%

P/E Metrics

39.58

-1.60

-1.60

Analyst Price Target & Rating

$175.00

$204.00

$159.00

Neutral

3/5

34 Analysts

-10.65%

Financial Health Scores

2.31

8/9

-$495M

$50.83B

$26.7B

$2.3B

Key Metrics (TTM)

$73.11B

3.42

15.61

0.94

4.54%

4.10%

2.59%

5.55%

$88.58

145 days

Company Executives
Name Title
Meera Gopalakrishnan Senior VP & Global Chief Marketing Officer
Carla Burigatto Senior Vice President & Chief Communications Officer
Joseph Smith Senior Vice President & Chief Scientific Officer
Vitor Roque Executive Vice President & Chief Financial Officer
Denise Fleming Executive Vice President & Chief Information Officer
Elizabeth McCombs Executive Vice President & Chief Technology Officer
Michael Garrison Executive VP & President of Medical Segment and BioPharma Systems Segments
Michael C. Feld Executive VP & Chief Revenue Officer
Richard Byrd Executive Vice President & President of Interventional Segment
Thomas E. Polen Jr. President, Chief Executive Officer & Chairman
Lanesha T. Minnix Executive Vice President & General Counsel
Poll Results

No votes yet today — be the first to share your view!

About Becton, Dickinson and Company (NYSE:BDX) Stock

Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including ... needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.

Mike Garrison to Retire from BD

2026-07-22 06:55:00

FRANKLIN LAKES, N.J., July 22, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Dr. Michael (Mike) Garrison has informed the company of his intent to retire after more than 20 years with BD, effective Oct. 2.

My Top Dividend Growth Stock to Buy in July and Hold Forever

2026-07-20 11:45:00

Here's a 2.7% dividend yield that has been growing by 10%-plus annually -- and it's undervalued, too.

BD to Announce Financial Results for its Third Quarter of Fiscal 2026

2026-07-09 16:15:00

FRANKLIN LAKES, N.J., July 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m.

Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?

2026-07-08 13:10:22

Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom

2026-07-07 17:30:00

Becton, Dickinson supplies equipment whose demand is soaring due to the rise of GLP-1 medicines. Abbott Laboratories' most important growth driver could benefit from greater adoption of GLP-1 drugs.

5 Dividend Kings Long-Term Investors Should Own for the Next 20 Years

2026-07-07 14:00:00

Investors can count on these stocks about as much as any to continue their decades-long runs of excellence.

Becton, Dickinson - Stable Undervaluation In 1Q26, Upside Is There

2026-07-01 11:32:19

Becton, Dickinson and Company is undervalued, trading at 12–13x P/E despite forecasted 7%–8% annual growth and improving fundamentals. BDX's sector-wide pressures are driven by cautious hospital spending, higher rates, and capital rotation into AI, but its core operations remain robust. BDX maintains a BBB rating, conservative leverage, a 2.78% dividend with 44+ years of increases, and is executing $2B in buybacks while retiring $2.1B in debt.

BD Awarded Vizient Innovative Technology Contract for CentroVena One™ Insertion System

2026-06-23 06:50:00

Recognition from Vizient validates CentroVena One™ as a breakthrough innovation designed to simplify central line insertion and enhance patient and clinician safety FRANKLIN LAKES, N.J., June 23, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its BD® CentroVena One™ Insertion System has been awarded an Innovative Technology contract from Vizient®, the nation's largest provider-driven healthcare performance improvement company.

Frequently Asked Questions

What is the current Becton, Dickinson and Company (BDX) stock price?

Becton, Dickinson and Company(NYSE:BDX) stock price is $156.36 in the last trading session. During the trading session, BDX stock reached the peak price of $187.35 while $127.58648 was the lowest point it dropped to. The percentage change in BDX stock occurred in the recent session was 2.22% while the dollar amount for the price change in BDX stock was $3.39.

BDX's industry and sector of operation?

The NYSE listed BDX is part of Medical - Instruments & Supplies industry that operates in the broader Healthcare sector.

Who are the executives of BDX?

Meera Gopalakrishnan | Senior VP & Global Chief Marketing Officer
Carla Burigatto | Senior Vice President & Chief Communications Officer
Joseph Smith | Senior Vice President & Chief Scientific Officer
Vitor Roque | Executive Vice President & Chief Financial Officer
Denise Fleming | Executive Vice President & Chief Information Officer

How many employees does BDX have?

Number of BDX employees currently stands at 72000. BDX operates from 1 Becton Drive, Franklin Lakes, NJ 07417-1880, US.

Link for BDX official website?

Official Website of BDX is: https://www.bd.com

How do I contact BDX?

BDX could be contacted at phone #201 847 6800 and can also be accessed through its website. BDX operates from 1 Becton Drive, Franklin Lakes, NJ 07417-1880, US.

How many shares of BDX are traded daily?

The average number of BDX shares traded daily for last 3 months was 2.76M.

What is the market cap of BDX currently?

The market value of BDX currently stands at $56.65B with its latest stock price at $156.36